Clicky

Innoviva, Inc.(INVA)

Description: Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.


Keywords: Medicine Drugs Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Respiratory Products Organofluorides Treatment Of Chronic Obstructive Pulmonary Disease Combination Drugs Fluticasone Glucocorticoids Antero Corticosteroid Muscarinic Antagonists

Home Page: www.inva.com

INVA Technical Analysis

1350 Old Bayshore Highway
Burlingame, CA 94010
United States
Phone: 650 238 9600


Officers

Name Title
Mr. Pavel Raifeld C.F.A. Chief Exec. Officer
Ms. Marianne Zhen CPA Chief Accounting Officer & Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 3.9636
Price-to-Book MRQ: 1.4438
Price-to-Sales TTM: 2.4232
IPO Date: 2004-10-05
Fiscal Year End: December
Full Time Employees: 5
Back to stocks